• Affibody journey: from ABY-025, a HER2 directed PET tracer to ABY-271 HER2 targeting radioligand therapy

• Enhancing ABY-271 with Albumod technology and making strategic choices: chelator and radioisotope in ABY-271

• Designing first-in-human phase 1/2 clinical study based on ABY-025/ preclinical ABY-271 insights